Published in Br J Clin Pharmacol on May 01, 1986
Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects. Br J Clin Pharmacol (1991) 0.84
Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy. Br J Clin Pharmacol (1988) 0.77
Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol (1979) 3.32
Assessment of antipyrine kinetics by measurement in saliva. Br J Clin Pharmacol (1976) 2.78
The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther (1979) 2.54
The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. Br J Clin Pharmacol (1976) 1.88
Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers. Eur J Clin Pharmacol (1974) 1.68
Assessment of the drug metabolism capacity of the liver. Br J Clin Pharmacol (1982) 1.51
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol (1984) 1.24
Effect of rifampicin on metoprolol and antipyrine kinetics. Br J Clin Pharmacol (1982) 1.15
Effects of physical stress on the disposition of drugs eliminated by the liver in man. J Pharmacol Exp Ther (1974) 1.02
A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs. Br J Clin Pharmacol (1980) 1.01
Effect of surgery under general anaesthesia on antipyrine clearance. Br J Clin Pharmacol (1978) 0.98
Salivary antipyrine half-life: a useful measure of hepatic drug metabolism. Br J Clin Pharmacol (1976) 0.88
Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J (1970) 5.88
Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J (1970) 5.81
Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet (1995) 4.98
Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ (2007) 3.26
Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol (2007) 2.97
Comprehensive clinical drug information service: first year's experience. Br Med J (1977) 2.77
Serum-phenytoin levels in management of epilepsy. Lancet (1975) 2.36
Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia (1999) 2.29
Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet (1984) 2.20
Changing patterns of self-poisoning in a UK health district. QJM (1996) 2.13
Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. Hum Mol Genet (1997) 2.02
Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol (1979) 1.95
Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) (1984) 1.83
Clinical pharmacokinetics of propranolol. Clin Pharmacokinet (1979) 1.81
Anticoagulants in venous thromboembolism. BMJ (1988) 1.77
A pharmacodynamic evaluation of midazolam as an antiepileptic compound. J Neurol Neurosurg Psychiatry (1986) 1.77
Lidocaine plasma protein binding. Clin Pharmacol Ther (1980) 1.74
Adenosine stimulates respiration in man. Br J Clin Pharmacol (1985) 1.67
Safety of late acetylcysteine treatment in paracetamol poisoning. Hum Exp Toxicol (1990) 1.65
The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentration. Br J Clin Pharmacol (1981) 1.63
Random and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an example. Br J Clin Pharmacol (2001) 1.63
Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia (1989) 1.62
Predicting patients' warfarin requirements. Lancet (1977) 1.61
External quality assessment of Syva Emit and Abbott TDx II assays for methotrexate in serum. Ther Drug Monit (1996) 1.59
Water intoxication in epileptic patients receiving carbamazepine. J Neurol Neurosurg Psychiatry (1978) 1.56
Quality control in drug measurement. Ther Drug Monit (1980) 1.56
Phosphate enemas in childhood: cause for concern. BMJ (1991) 1.55
Liver enzyme induction by anticonvulsant drugs, and its relationship to disturbed calcium and folic acid metabolism. J Clin Pharmacol (1973) 1.54
Adrenergic control of tendon jerk reflexes in man. Br J Pharmacol (1973) 1.54
Absorption of diazepam from the rectum and its effect on interictal spikes in the EEG. Epilepsia (1982) 1.50
The plasma protein binding of basic drugs. Br J Clin Pharmacol (1986) 1.49
Atropine as possible contaminant of comfrey tea. Lancet (1989) 1.43
Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects. Clin Pharmacol Ther (1981) 1.42
Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet (1979) 1.42
Community exposures to chemical incidents: development and evaluation of the first environmental public health surveillance system in europe. J Epidemiol Community Health (2000) 1.39
The effect of intravenous aminophylline on essential tremor. Br J Clin Pharmacol (1997) 1.38
Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmacol (1979) 1.36
The response of essential tremor to propranolol: evaluation of clinical variables governing its efficacy on prolonged administration. J Neurol Neurosurg Psychiatry (1983) 1.36
Acute effects of intravenous phenytoin on the frequency of inter-ictal spikes in man. Br J Clin Pharmacol (1983) 1.36
Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med (1980) 1.35
Metoprolol and propranolol in essential tremor: a double-blind, controlled study. J Neurol Neurosurg Psychiatry (1981) 1.35
Lignocaine disposition in blood in epilepsy. Br J Clin Pharmacol (1981) 1.35
Plasma protein binding interaction between phenytoin and valproic acid in vitro. Br J Clin Pharmacol (1978) 1.34
Sex-related differences in the plasma protein binding of lignocaine and diazepam. Br J Clin Pharmacol (1981) 1.32
Phenylethylmalonamide in essential tremor. A double-blind controlled study. J Neurol Neurosurg Psychiatry (1981) 1.31
Clobazam as adjunctive treatment in refractory epilepsy. Br Med J (Clin Res Ed) (1983) 1.31
Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. Br J Clin Pharmacol (1979) 1.30
Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients. Clin Pharmacol Ther (1980) 1.29
Transient bradycardia and subsequent sinus tachycardia produced by intravenous adenosine in healthy adult subjects. Br J Clin Pharmacol (1986) 1.29
Attitudes of GPs to the care of people with epilepsy. Fam Pract (1998) 1.29
Theophylline: biochemical pharmacology and pharmacokinetics. J Int Med Res (1979) 1.28
High-performance liquid chromatographic analysis of isoniazid and acetylisoniazid in biological fluids. J Chromatogr (1983) 1.27
Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance. Br J Clin Pharmacol (1984) 1.27
Reduction of free testosterone by antiepileptic drugs. Br Med J (Clin Res Ed) (1982) 1.26
Free and total plasma theophylline concentrations in chronic airflow obstruction. Thorax (1984) 1.26
Phenytoin intoxication induced by sulthiame in epileptic patients. J Neurol Neurosurg Psychiatry (1974) 1.26
Accidental poisoning in children: can we admit fewer children with safety? Arch Dis Child (1991) 1.25
Difference in the central actions of phenytoin and phenobarbitone in man, measured by critical flicker fusion threshold. Eur J Clin Pharmacol (1973) 1.25
Involuntary movements caused by phenytoin intoxication in epileptic patients. J Neurol Neurosurg Psychiatry (1975) 1.24
A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol (1984) 1.24
A simple method for determining acetylator phenotype using isoniazid. Br J Clin Pharmacol (1986) 1.22
The framework of medical care for epilepsy. Health Trends (1987) 1.22
The impact of nationally distributed guidelines on the management of paracetamol poisoning in accident and emergency departments. National Poison Information Service. J Accid Emerg Med (1998) 1.22
Recent developments in the management of paracetamol (acetaminophen) poisoning. Drug Saf (1992) 1.21
A method to prevent the loss of isoniazid and acetylisoniazid in human plasma. Br J Clin Pharmacol (1983) 1.20
Determinants of the plasma protein binding of theophylline in health. Br J Clin Pharmacol (1983) 1.19
Effect of a single oral dose of propranolol on essential tremor: a double-blind controlled study. Ann Neurol (1983) 1.19
Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther (1982) 1.19
Monitoring effects of oral anticoagulants during treatment with heparin. Br Med J (Clin Res Ed) (1984) 1.18
Intravenous adenosine in the treatment of supraventricular tachycardia: a dose-ranging study and interaction with dipyridamole. Br J Clin Pharmacol (1986) 1.16
Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction. Clin Pharmacol Ther (1981) 1.16
The effects of age and smoking on the plasma protein binding of lignocaine and diazepam. Br J Clin Pharmacol (1985) 1.16
Reduction of oral bioavailability of lignocaine by induction of first pass metabolism in epileptic patients. Br J Clin Pharmacol (1979) 1.15
Methods of assessment of antiepileptic drugs. Br J Clin Pharmacol (1981) 1.14
Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. Br J Clin Pharmacol (1975) 1.13
Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol (1987) 1.13
Drug interactions with phenytoin. Drugs (1981) 1.12
Interactions with antiepileptic drugs. Drugs (1977) 1.12
Adenosine-induced respiratory stimulation in man depends on site of infusion. Evidence for an action on the carotid body? Br J Clin Pharmacol (1987) 1.12
The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia (1999) 1.11
Predicting the dose of warfarin for therapeutic anticoagulation. Thromb Haemost (1982) 1.09
Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. QJM (2002) 1.09
Reversal of competitive neuromuscular blockade by RX 67668 in normal volunteers. Br J Pharmacol (1972) 1.09
Rectal absorption of diazepam in epileptic children. Arch Dis Child (1982) 1.07
The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy. Br J Clin Pharmacol (1986) 1.07
Should we routinely measure free plasma phenytoin concentration? Br J Clin Pharmacol (1984) 1.07
Hemlock water dropwort poisoning--a review. Clin Toxicol (1978) 1.05
Effect of low-dose phenobarbitone on five indirect indices of hepatic microsomal enzyme induction and plasma lipoproteins in normal subjects. Br J Clin Pharmacol (1981) 1.05
Importance of blood-collection tubes in plasma lidocaine determinations. Clin Chem (1979) 1.05
Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res (1987) 1.04
The action of general anaesthetic agents on root responses of the frog isolated spinal cord. Br J Pharmacol (1969) 1.04
Pharmacokinetics of the hypnotic benzodiazepine, temazepam. Br J Clin Pharmacol (1979) 1.04
When should plasma drug levels be monitored? Drugs (1979) 1.03
Important drug-drug interactions in the elderly. Drugs Aging (1998) 1.02
A comparative study of antipyrine and lignocaine disposition in normal subjects and in patients treated with enzyme-inducing drugs. Br J Clin Pharmacol (1980) 1.01
Presystemic drug elimination. Annu Rev Pharmacol Toxicol (1979) 1.01